Approved: May 10, 1996.

Stephen D. Potts,

Director, Office of Government Ethics.

[FR Doc. 96–12222 Filed 5–15–96; 8:45 am]

BILLING CODE 6345–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Commission on Dietary Supplement Labels: Meeting No. 4; Opportunity To Provide Comments

AGENCY: Office of Disease Prevention and Health Promotion.

ACTION: Commission on Dietary Supplement Labels: Notice of meeting #4; Opportunity to provide comments.

SUMMARY: The Department of Health and Human Services (HHS) is (a) providing notice of the fourth meeting of the Commission on Dietary Supplement Labels, and (b) soliciting oral and written comments.

DATES: (1) The Commission will meet June 6, 1996, from 8:30 a.m. to 4:30 p.m. Eastern Daylight Time at the Clarion Plaza Hotel, 9700 International Drive, Orlando, Florida 32819–8114; (2) Written comments on the scope and intent of the Commission's objectives may be submitted by 5:00 p.m. E.D.T. on June 30, 1996 to the address noted below.

FOR FURTHER INFORMATION CONTACT: Kenneth D. Fisher, Ph.D., Executive Director, Commission on Dietary Supplement Labels, Office of Disease Prevention and Health Promotion, Room 738G, Hubert Humphrey Building, 200 Independence Ave. S.W., Washington, D.C. 20201, (202) 690–7102.

SUPPLEMENTARY INFORMATION:

Commission's Task

Public Law 103–417, Section 12, authorized the establishment of a Commission on Dietary Supplement Labels whose seven members have been appointed by the President. The appointments to the Commission by the President and the establishment of the Commission by the Secretary of Health and Human Services reflect the commitment of the President and the Secretary to the development of a sound and consistent regulatory policy on labeling of dietary supplements.

The Commission is charged with conducting a study and providing recommendations for regulation of label claims and statements for dietary supplements, including the use of supplemental literature in connection with their sale and, in addition, procedures for evaluation of label claims. The Commission is expected to evaluate how best to provide truthful, scientifically valid, and nonmisleading information to consumers in order that they may make informed health care choices for themselves and their families. The Commission's study report may include recommendations on legislation, if appropriate and necessary.

Announcement of Meeting

The Commission's fourth meeting will be June 6, 1996, 8:30 a.m. to 4:30 p.m. Eastern Daylight Time. The meeting will be held in the Salon Room at the Clarion Plaza Hotel, 9700 International Drive, Orlando, Florida 32819–8114. The agenda will include (a) oral comments from interested parties and the general public, (b) identification of additional information needs, and (c) discussion of dietary supplement label information.

Public Participation at Meeting

The meeting is open to the public. However, space is limited. Both oral and written comments from the public will be accepted, but oral comments at the meeting will be limited to a maximum of five minutes per presenter; thus, organizations and persons wishing to make their views known to the Commission should use the time for oral presentation to summarize their written comments. Persons and organizations that have not made presentations or submitted statements previously will be given preference on the agenda. Members of the Commission may wish to question the presenters following each oral presentation. Please request the opportunity to present oral comments in writing and provide fifteen (15) copies of the written comments from which the oral presentation is abstracted to the address above by May 29, 1996. If you will require a sign language interpreter, please call Sandra Saunders (202) 690–7102 by 4:30 p.m. E.D.T. on May 29, 1996.

Written Comments

By this notice, the Commission is soliciting submissions of written comments, views, information, and data pertinent to the Commission's task. Comments should be sent to Kenneth D. Fisher, Ph.D., Executive Director of the Commission at the Office of Disease Prevention and Health Promotion, Room 738G, Hubert Humphrey Building, 200 Independence Ave. S.W., Washington, D.C. 20201, by 5:00 p.m. E.D.T. on June 30, 1996.

Dated: May 8, 1996.

Claude Earl Fox,

Deputy Assistant Secretary for Health (Disease Prevention and Health Promotion), Department of Health and Human Services.

[FR Doc. 96–12223 Filed 5–15–96; 8:45 am]

BILLING CODE 4160–17–M

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case:

Michael W. Washabaugh, Ph.D., Johns Hopkins University: Based on an investigation conducted by the institution as well as information obtained by ORI during its oversight review, ORI found that Michael W. Washabaugh, Ph.D., Associate Professor of Biochemistry, Department of Biochemistry, Johns Hopkins University School of Hygiene and Public Health, committed scientific misconduct by reporting falsified and/or fabricated research data in two grant applications submitted to the National Institutes of Health.

Specifically, Dr. Washabaugh (1) reported falsified results of experiments concerning the number of DTNB (5,5′-dithiobis [2-nitrobenzoate]) reactive thiols in native thiamin binding protein in a grant application entitled ''Mechanism of a periplasmic permease,'' and (2) reported falsified and/or fabricated portions of data presented in two separate figures to support his hypothesis of thiamin binding to thiamin binding protein in grant applications entitled ''Mechanism of a periplasmic permease'' and ''Mechanisms of enzymic and non-enzymic thiamin reactions.''

Dr. Washabaugh has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the four (4) year period beginning May 7, 1996, to exclude himself from:

(1) Any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations), and

(2) Serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

No scientific publications were required to be corrected as part of this Agreement.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Chris B. Pascal, J.D.,

Acting Director, Office of Research Integrity.

[FR Doc. 96–12263 Filed 5–15–96; 8:45 am]

BILLING CODE 4160–17–P

Agency for Health Care Policy and Research

Notice of Advisory Committee Meetings

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following advisory committees scheduled to meet during the month of June 1996:

Name: Health Services Research Review Subcommittee.

Date and Time: June 6–7, 1996, 8:30 a.m.

Place: Ramada Inn, 1775 Rockville Pike, Conference Room TBA, Rockville, Maryland 20852. Open June 6, 1996, 8:30 a.m. to 9:00 a.m. Closed for remainder of meeting.

Purpose: The Subcommittee is charged with the initial review of grant applications proposing analytical and theoretical research on costs, quality, access, and efficiency of the delivery of health services for the research grant program administered by the Agency for Health Care Policy and Research (AHCPR).

Agenda: The open session of the meeting on June 6, from 8:30 a.m. to 9:00 a.m., will be devoted to a business meeting covering administrative matters and reports. During the closed session, the Subcommittee will be reviewing and discussing grant applications dealing with health services research issues. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6), the Administrator, AHCPR, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members, minutes of the meeting, or other relevant information should contact Patricia G. Thompson, Ph.D., Scientific Review Administrator, Office of Scientific Affairs, Agency for Health Care Policy and Research, Suite 400, Executive Office Center, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594–1437x1607.

Name: Health Services Research Dissemination Study Section.

Date and Time: June 27, 1996, 7:30 a.m.

Place: Doubletree Hotel, 1750 Rockville Pike, Conference Room TBA, Rockville, Maryland 20852. Open June 27, 1996, 7:30 a.m. to 8:00 a.m. Closed for remainder of meeting.

Purpose: The Study Section is charged with the review of and making recommendations on grant applications for Federal support of conferences, workshops, meetings, or projects related to dissemination and utilization of research findings, and AHCPR liaison with health care policy makers, providers, and consumers.

Agenda: The open session of the meeting on June 27, from 7:30 a.m. to 8:00 a.m., will be devoted to a business meeting covering administrative matters and reports. During the closed session, the Subcommittee will be reviewing and discussing grant applications dealing with health services research issues. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6), the Administrator, AHCPR, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members, minutes of the meeting, or other relevant information should contact Linda Blankenbaker, Scientific Review Administrator, Office of Scientific Affairs, Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594–1437x1603.

Agenda items for all meetings are subject to change as priorities dictate.

Dated: May 8, 1996.

Clifton R. Gaus,

Administrator.

[FR Doc. 96–12361 Filed 5–15–96; 8:45 am]

BILLING CODE 4160–90–M

Centers for Disease Control and Prevention

[30 DAY–11]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Office on (404) 639–7090.

The following requests have been submitted for review since the last publication date on May 9, 1996.

Proposed Project

1. Intensive-Care Antimicrobial Resistance Epidemiology (Project ICARE), Phase II—NEW—Antibiotic resistance is estimated to cost as much as 4 billion dollars a year to the health care system in the United States and the number of resistant microorganisms is increasing. For example, data reported to the National Nosocomial Infections Surveillance (NNIS) system demonstrated a 20-fold increase, between January 1989 and March 1993, in the percentage of enterococci associated with nosocomial infections that are resistant to vancomycin (VRE). Additional analysis of NNIS data has demonstrated that other antibiotic resistant nosocomial pathogens have also increased in recent years. One of the major factors limiting the understanding of antibiotic resistance among nosocomial pathogens is the lack of information on the relationship between the amount and kind of antibiotic used in hospitals and the emergence of resistance.

This proposed one year study, called Project ICARE, will collect data on the amount of antibiotics used in 50 NNIS hospitals and the antibiotic susceptibility patterns found in certain bacterial pathogens isolated in these hospitals' microbiology laboratories between June 1996 and June 1997. Further, new mechanisms of resistance will be studied on specific antibiotic-resistant isolates that will be sent to CDC from these laboratories. A successful pilot study involving eight NNIS hospitals was conducted between August 1994 and January 1995 to study the feasibility of collecting such information.

After initially setting up the project with information on the different intensive care units (ICUs) and wards, the hospital will provide three different types of data each month: (1) Summary of the amount of parenteral and oral antibiotics, by generic group, reported by the pharmacy, (2) summary of the number of isolates, by species, susceptible, intermediate or resistant to various antibiotics reported by the microbiology laboratory, and (3) actual isolates of resistant pathogens to be sent to by the microbiology laboratory to CDC. For antibiotics used and number of isolates in each of the susceptibility categories, separate data are to be reported for each ICU, all other inpatients, and outpatients (antibiotic use among outpatients is not collected). Data collection forms for summary data from the microbiology laboratory and pharmacy have been created to assist in recording the data; however, the data will be entered into a computer software created by CDC specifically for Project ICARE. The software will be provided to the hospitals at no cost. Data will be transmitted to CDC by floppy disk or by electronic transfer when it become available in the NNIS system in 1996.